Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/29/2012EP2423196A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof
02/29/2012EP2423194A1 NOVEL THYROID HORMONE beta RECEPTOR AGONIST
02/29/2012EP2423190A1 Compounds Exhibiting PGD 2 Receptor Antagonism
02/29/2012EP2423182A1 Diacylethylenediamine compound
02/29/2012EP2423177A1 Analogs of geranylgeranylacetone (GGA)
02/29/2012EP2423176A1 Carboxylic acid compound
02/29/2012EP2422849A1 Composition of Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422848A1 Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422815A1 Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422814A1 Remedy for cartilage-related diseases
02/29/2012EP2422791A1 Antiviral phosphinate compounds
02/29/2012EP2422790A1 Paramyxovirus family inhibitors and methods of use thereof
02/29/2012EP2422789A1 Injectable coposition comprising sodium deoxycholate
02/29/2012EP2422788A2 Benzodiazepines and compositions and uses thereof
02/29/2012EP2422787A1 Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
02/29/2012EP2422786A1 New medicine combinations for treating respiratory diseases
02/29/2012EP2422785A1 Method for predicting therapeutic effect of chemotherapy on renal cell cancer
02/29/2012EP2422784A1 Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422783A1 Pharmaceutical Composition
02/29/2012EP2422782A1 Methods of Using Sustained Release Aminopyridine Compositions
02/29/2012EP2422781A1 Resistance-repellent retroviral protease inhibitors
02/29/2012EP2422780A1 Resistance-repellent retroviral protease inhibitors
02/29/2012EP2422779A1 Selective ep4 receptor agonistic substance for treatment of cancer
02/29/2012EP2422778A1 Titration of tapentadol
02/29/2012EP2422777A1 Synergistic effect of modulators for NO metabolism and NADPH oxidase during sensitization of tumour cells
02/29/2012EP2422776A1 Polyarginine nanocapsules
02/29/2012EP2422774A1 Pharmaceutical composition containing a tetrahydrofolic acid
02/29/2012EP2422769A1 Compositions and methods for improved organ transplant preservation and acceptance
02/29/2012EP2422768A2 Penetrating pharmaceutical foam
02/29/2012EP2422767A2 Methods for preparing dry powder compositions of glycopyrrolate
02/29/2012EP2422766A2 Methods for preparing dry powder compositions of glycopyrrolate
02/29/2012EP2422629A1 Methods for enhancing cognition and/or memory using maltodextrins
02/29/2012EP2421970A1 Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
02/29/2012EP2421968A1 Method for the treatment of acute myeloid leukemia
02/29/2012EP2421967A2 Compositions, kits and methods for promoting ischemic and diabetic wound healing
02/29/2012EP2421882A2 Angiogenesis inhibitors
02/29/2012EP2421880A1 Nucleic acid delivery compositions and methods
02/29/2012EP2421879A2 Novel 7-deazapurine nucleosides for therapeutic uses
02/29/2012EP2421878A1 Anionic oligosaccharide conjugates
02/29/2012EP2421877A1 Anionic conjugates of glycosylated bacterial metabolite
02/29/2012EP2421872A1 Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
02/29/2012EP2421871A1 Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
02/29/2012EP2421870A2 Modulators of 5-ht receptors and methods of use thereof
02/29/2012EP2421869A1 Rifamycin derivatives
02/29/2012EP2421866A1 3,3'-spiroindolinone derivatives and their use for cancer
02/29/2012EP2421864A1 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
02/29/2012EP2421863A1 Substituted naphthyridine derivatives and their medical use
02/29/2012EP2421862A1 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
02/29/2012EP2421860A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421859A1 Thiazole derivatives and their use as p2y12 receptor antagonists
02/29/2012EP2421858A1 Thioxanthene derivatives for the treatment of infectious diseases
02/29/2012EP2421856A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421855A1 Diaryl ethers
02/29/2012EP2421854A1 Inhibitors of bruton's tyrosine kinase
02/29/2012EP2421852A1 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
02/29/2012EP2421851A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421850A1 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
02/29/2012EP2421849A1 Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
02/29/2012EP2421848A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421847A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421846A1 5-alkynyl-pyridines
02/29/2012EP2421845A1 Antiviral compounds and uses thereof
02/29/2012EP2421844A1 Thiophene inhibitors of ikk-b serine-threonine protein kinase
02/29/2012EP2421843A2 Process for the preparation of olopatadine
02/29/2012EP2421841A1 Improved method of achieving and maintaining a specified alkylene oxide production parameter with a high efficiency catalyst
02/29/2012EP2421836A1 2-aryl imidazoline derivatives
02/29/2012EP2421835A1 N-pyrazolyl carboxamides as crac channel inhibitors
02/29/2012EP2421834A1 Pyrazole and triazole carboxamides as crac channel inhibitors
02/29/2012EP2421833A1 Resorcinol derivatives as hsp90 inhibitors
02/29/2012EP2421831A1 Heterocyclic antiviral compounds
02/29/2012EP2421830A2 2,5-disubstituted arylsulfonamide ccr3 antagonists
02/29/2012EP2421829A2 2,5-disubstituted arylsulfonamide ccr3 antagonists
02/29/2012EP2421828A2 Piperidine derivatives as inhibitors of renin
02/29/2012EP2421825A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421824A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421823A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
02/29/2012EP2421612A1 Heterocyclic compounds as mek inhibitors
02/29/2012EP2421562A1 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
02/29/2012EP2421548A1 Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
02/29/2012EP2421547A1 Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
02/29/2012EP2421541A1 Novel use
02/29/2012EP2421540A1 A novel formulation of meloxicam
02/29/2012EP2421539A1 Methods of treating a pulmonary bacterial infection using fluoro-quinolones
02/29/2012EP2421538A1 Heteroaryl compounds and uses thereof
02/29/2012EP2421537A1 Pyrazolylaminopyridines as inhibitors of fak
02/29/2012EP2421536A1 Methods of treatment for solid tumors
02/29/2012EP2421535A1 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
02/29/2012EP2421534A1 Liquid formulations of salts of 1-ý2-(2,4-dimethylphenylsulfanyl)phenyl¨piperazine
02/29/2012EP2421533A1 Novel anti-inflammatory agents
02/29/2012EP2421532A2 Spiperone derivatives and methods of treating disorders
02/29/2012EP2421531A1 Use of nifuratel to treat infections caused by atopobium species
02/29/2012EP2421530A1 A novel formulation of metaxalone
02/29/2012EP2421529A2 Siderophore conjugate immunogenic compositions and vaccines
02/29/2012EP2421528A1 Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
02/29/2012EP2421527A1 Methods for improving pharmacokinetics
02/29/2012EP2421526A2 A topical parasiticide composition
02/29/2012EP2421525A1 A novel formulation of diclofenac
02/29/2012EP2421524A2 Chemosensory receptor ligand-based therapies
02/29/2012EP2421523A1 Method of treating or preventing a convulsive disorder in a patient in need thereof
02/29/2012EP2421522A1 Paracetamol for parenteral administration
1 ... 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 ... 7860